While Akorn works to revive its fortunes, the FDA hits it with another warning letter
Akorn just can’t dig itself out of its hole.
The specialty generic drugmaker has received yet another warning letter from the FDA this year. Without disclosing any specifics, the Lake Forest, Illinois-based drugmaker on Wednesday said the US regulator had issued the letter, citing an inspection of its Somerset, New Jersey manufacturing facility in July and August of 2018. The company’s shares $AKRX dipped about 1.7% to $4.65 before the bell.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.